Acute Respiratory Distress Syndrome as the Initial Clinical Manifestation of an Antisynthetase Syndrome

Seo-Hyun Kim, M.D. and I-Nae Park, M.D.
Department of Internal Medicine, Inje University Seoul Paik Hospital, Seoul, Korea

Antisynthetase syndrome has been recognized as an important cause of autoimmune inflammatory myopathy in a subset of patients with polymyositis and dermatomyositis. It is associated with serum antibody to aminoacyl-transfer RNA synthetases and is characterized by a constellation of manifestations, including fever, myositis, interstitial lung disease, mechanic’s hand-like cutaneous involvement, Raynaud phenomenon, and polyarthritis. Lung disease is the presenting feature in 50% of the cases. We report a case of a 60-year-old female with acute respiratory distress syndrome (ARDS), which later proved to be an unexpected and initial manifestation of anti-Jo-1 antibody–positive antisynthetase syndrome. The present case showed resolution of ARDS after treatment with high-dose corticosteroids. Given that steroids are not greatly beneficial in the treatment of ARDS, it is likely that the improvement of the respiratory symptoms in this patient also resulted from the prompt suppression of the inflammatory systemic response by corticosteroids.

Keywords: Respiratory Distress Syndrome, Adult; Immunoglobulins; Antisynthetase Syndrome

Introduction

The idiopathic inflammatory myopathies (IIM) are a rare group of heterogeneous connective tissue diseases affecting skeletal muscle and other organ systems. Subsets of IIM are clinically and pathologically assigned to one of three general subcategories: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. The lung is one of the most common extramuscular targets in IIM, and interstitial lung disease (ILD) is a prevalent and often devastating manifestation of IIM. IIM-associated ILD (IIM-ILD) contributes to nearly 80% of the mortality in IIM with a reported prevalence of 65% of newly diagnosed IIM cases. The antisynthetase syndrome is characterized by the presence of any one of several antisynthetase autoantibodies (perhaps occurring in up to one-third of DM and PM patients) in combination with fever, Raynaud’s phenomenon, polyarthritis, myositis, ILD, and “mechanic hands.” ILD often dominates the clinical picture and may be the presenting feature of the syndrome, as the acute onset of fever and respiratory distress occurs in nearly 50% of patients.

We report a case of a 60-year-old female with acute respiratory distress syndrome (ARDS), which later proved to be an unexpected and initial manifestation of anti-Jo-1 antibody–positive antisynthetase syndrome. The present case showed resolution of ARDS after treatment with high-dose corticosteroids. Given that steroids are not greatly beneficial in the treatment of ARDS, it is likely that the improvement of the respiratory symptoms in this patient also resulted from the prompt suppression of the inflammatory systemic response by corticosteroids.

Case Report

A 60-year-old woman was admitted to the Emergency Department (ED) of our hospital for cough, shortness of breath, chills, and myalgia. There was no sputum. She was a tourist from Japan and had come to Korea three days earlier. The patient had been in good health until the past week, when
ARDS and antisynthetase syndrome

she developed a fever and headache. In response, she took acetaminophen for 3 days. She had no history of smoking and was not on any continuous therapy. On arrival to the ED, the patient's body temperature was 37.8°C, blood pressure 130/74 mm Hg, pulse rate 82 beats per minute, respiratory rate 24 breaths per minute, and oxygen saturation 86% while breathing ambient air. Crackles were heard at the base of lungs. Respiratory failure was confirmed by the arterial blood gas: PO₂ 51 mm Hg, PCO₂ 32 mm Hg, and pH 7.52. The white blood cell count was 7,500/μL (neutrophils, 80%; lymphocytes, 12%; monocytes, 5%) and a hemoglobin value of 13.0 g/dL. C-reactive protein was increased to 12.7 mg/dL (normal, 0–0.8 mg/dL). Procalcitonin was <0.05 ng/mL (normal, <0.05 ng/mL). Chest radiography (Figure 1B) showed bilateral infiltrates in both lower fields. The patient was admitted to the Respiratory Department, where she received antibiotics (intravenous levofloxacin plus piperacillin-tazobactam plus oral clarithromycin) and oxygen. Further blood tests were conducted, which showed elevations of creatinine kinase (448 IU/L), lactate dehydrogenase (596 IU/L), aspartate aminotransferase (144 IU/L), and alanine aminotransferase (128 IU/L). On the second day of hospitalization, the patient's respiratory failure worsened, and she was transferred to the intensive care unit, where endotracheal intubation and mechanical ventilation were performed. As she progressed to respiratory failure (Figure 1C), we thought she had severe community-acquired pneumonia, and we administered hydrocortisone intravenously (100 mg then 50 mg every 6 hours) for 3 days. After 4 days on the ventilator (Figure 1D), we removed the endotracheal tube. However, two days later, the patient's body temperature was 39°C, her respiratory rate was 35 breaths per minute, and she complained of general weakness and dyspnea. Due to the development of ARDS (Figure 1E), we re-intubated the patient and began mechanical ventilation again. We thought her condition may be ventilator-associated pneumonia, and changed antibiotics from levofloxacin plus piperacillin-tazobactam to meropenem plus vancomycin. However, the patient's high fever persisted and her chest radiography worsened. On the eighth day of hospitalization, there was still no improvement and the microbiological evaluation provided no evidence for bacterial, fungal, or viral infection under repeated endotracheal aspiration cultures and protected bronchial washing culture. We suspected inflammatory myopathy with ILD due to the increased muscle and liver enzyme values. Especially, creatinine kinase was elevated to >2,000 IU/L. Thus, we checked specific markers for connective tissue diseases. In addition, we reviewed her past medical history from her daughter. Before admission, the patient had suffered from frequent oral ulcers and eye dryness for several weeks. Two months ago, she underwent chest radiography (Figure 1A) at a Japanese hospital and the results were normal. One week before she arrived in Korea, she underwent a blood test due to multiple arthralgias, which showed a high value of lactate dehydrogenase (422 IU/L). While we screened for the specific markers for inflammatory myopathy, an empirical therapy with high-dose corticosteroids was started (intravenous pulses of 125 mg every 6 hours for one day tapered 60 mg/day). The therapy led to a significant improvement of PaO₂/FIO₂ ratio, and enabled to wean the patient from mechanical ventilation on the 11th day after intubation. On the 13th day of hospitalization, laboratory results revealed positive anti–Jo-1 antibody with 6.4 index (normal range, <1.0 index), aldolase with 22.9 U/L.

Figure 1. Chest X-ray film at 2 months prior to admission (A), on admission (B), before the first intubation (C), after the first extubation (D), after the second intubation (E), and at discharge (F).
(normal range, 0–7.6 U/L), and anti-Ro (SSA) antibody with >240 U/mL (normal range, <10 U/mL). Rheumatoid factor, antinuclear antibody, anti-La (SSB) antibody, anti-centromere antibody, anti–Sc-I antibody, anti–ds-DNA antibody, anti–ribonucleoprotein antibody, and anti-Sm antibody were all negative. On high-resolution computed tomography (HRCT) (Figure 2) after extubation, there were still irregular diffuse ground-glass opacity in both upper lungs and irregular patchy consolidation on both lower lungs without honeycombing. Although a histologic diagnosis was not made, we provisionally diagnosed the patient with ARDS as the initial clinical manifestation of an anti–Jo-1 antibody–positive antisynthetase syndrome. After 25 days of hospitalization (Figure 1F), the patient was discharged without oxygen. Figure 3 shows the whole course of laboratory values, clinical course, and treatments.

Discussion

Aminoacyl-tRNA synthetase (ARS) is a family of cytoplasmic enzymes that catalyze the formation of aminoacyl-tRNA from a specific amino acid and its cognate tRNA and play a crucial role in protein synthesis. Eight anti-ARS autoantibodies have been identified to date. These include antithistidyl (anti–Jo-1), anti–threonyl (anti–PL-7), anti–alanyl (anti–PL-12), anti–isoleucyl (anti-OJ), anti–glucyl (anti-EJ), anti-asparaginyl (anti–KS), anti–phenylalanyl (anti–Zo), and anti–tyrosyl-tRNA synthetases. Based on a unique combination of clinical features commonly observed in patients with anti-ARS autoantibodies, Targoff4 proposed a disease entity termed anti-synthetase syndrome. Antihistidyl tRNA synthetase antibody, often referred to as anti–Jo-1 antibody, is the most frequently detected antisynthetase autoantibody and is strongly associated with the presence of ILD in both PM and DM. In one large cohort study, ILD was identified in 86% of anti–Jo-1 antibody–positive myositis patients10.

The breadth of presentation in IIM-ILD ranges from asymptomatic basilar lung fibrosis to an acute, rapidly progressive condition associated with ARDS and respiratory failure3,6. The most common presenting symptoms are cough and dyspnea; however, IIM-ILD may be associated with asymptomatic lung disease, as evidenced by the high frequency of radiographic

Figure 2. High-resolution computed tomography (HRCT) after the second extubation when the patient was on prednisolone. On HRCT, there were still irregular diffuse ground glass opacities in both upper lobes (A) and irregular patchy consolidation in both lower lobes without honeycombing (B).

Figure 3. The time course of laboratory values including creatine kinase (CK), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST), and history of ventilator use and medications. Intravenous methylprednisolone was administered at a dose of 125 mg every 6 hours for 1 day, followed by oral prednisolone at a dose of 60 mg/day.
cally documented ILD. Of clinical importance, there is no correlation between the severity of lung involvement and the degree of myositis disease activity; yet, the severity of respiratory symptoms at presentation appears to correlate with the outcome in IIM-ILD. In particular, acute and rapidly progressive ILD, corresponding to ARDS with the histopathology of diffuse alveolar damage (DAD), can occur in any patient with IIM-ILD but is frequently seen with the antisynthetase syndrome, regardless of whether patients manifest complete forms of the syndrome or forms frustes.

Several histopathologic patterns have been described in IIM-ILD. The most common histology in IIM-ILD is non-specific interstitial pneumonia (NSIP), with a prevalence of approximately 80%. Usual interstitial pneumonia is less common than NSIP in IIM-ILD. DAD is the most rapidly progressive pathologic subset and carries worst prognosis. DAD, resembling the histological appearance associated with ARDS, is diffuse interstitial inflammation with edema and hyaline membrane production ultimately leading to organizing fibrosis. On HRCT, it is diffuse in appearance with ground glass consolidations and, in later stages, traction bronchiectasis and honeycombing may appear. Any initial HRCT pattern can rapidly deteriorate to ARDS, often leading to patient demise. In one retrospective case study, IILD patients with anti-ARS antibodies showed a chronic clinical course, lung-base predominant ground glass opacity with volume loss, NSIP and/or organizing pneumonia patterns, and a good response to corticosteroid treatment; however, some had a rapidly worsening courses and recurrence, despite therapy. In terms of prognosis, Yousem et al., studying the clinicopathologic pattern of 20 antisynthetase syndrome patients, found that the subgroup of patients presenting with an acute rapidly progressive hypoxemia had a worst prognostic histologic pattern due to the presence of DAD in five cases. This analysis highlights that a significant portion of these patients present with acute respiratory decompensation manifesting as pure DAD or DAD superimposed on underlying chronic symptomatic or asymptomatic fibrosing lung disease. Our patient followed a fulminant course, with fever, rapid progression of radiographic changes, and respiratory failure. Her clinical course was all consistent with acute interstitial pneumonia, although we did not obtain a surgical lung biopsy.

There are no approved agents in the treatment of IIM, and this lack of established treatment regimen extends to IIM-ILD. Nevertheless, corticosteroids remain the cornerstone of early treatment with initial doses at 1 mg/kg of the ideal body weight. In an effort to reduce treatment-related side effects, other immunosuppressive, steroid-sparing agents should be considered at the outset of therapy, particularly, when treating antisynthetase syndrome and other severe and progressive manifestations of ILD. Especially, given the relative rarity of ARDS complicating IIM, there is a paucity of studies to guide therapy. Perhaps the best approach for now is to increase the intensity of pulse cyclophosphamide, cyclosporine, or other immunosuppressive therapy earlier, especially in patients who have responded poorly, if at all, to conventional pulse steroid therapy. Tacrolimus, 100-fold more potent than cyclosporine in inhibiting T-cell activation, has also been used in concert with other immunosuppressive agents. Fortunately, our patient’s ARDS secondary to antisynthetase syndrome was resolved under treatment with a high dose of steroids, resulting in the patient’s discharge without oxygen.

In conclusion, given that steroids are not greatly beneficial in the treatment of ARDS, it is likely that the improvement of the respiratory symptoms in this patient also resulted from the prompt suppression of the inflammatory systemic response by corticosteroid.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008;59:677-85.
2. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004;63:297-301.
3. Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 2010;6:108-19.
4. Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20:857-80.
5. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
6. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008;63:53-9.
7. Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminocyl-rRNA synthetase autoantibodies. Intern Med 2010;49:361-9.
8. Bajocchi G, Piro R, Lombardini C, Cavazza A, Facciolongo N. Acute respiratory distress syndrome: an undercover antisynthetase syndrome: a case report and a review of the literature. Clin Exp Rheumatol 2012;30:424-8.
9. Polosa R, Di Mauro C, Spampinato B, Castelli L, D’Amico G, Edwards CJ, et al. A patient with antihistidyl-tRNA synthetase positive polymyositis presenting as acute respiratory distress syndrome. J Clin Rheumatol 2008;14:219-21.

10. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009;60:2183-92.

11. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF; et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614-22.

12. Huh JW, Kim DS, Lee CK, Yoo B, Seo JB, Kitaichi M, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007;101:1761-9.

13. Yousem SA, Gibson K, Kaminski N, Oddis CV, Ascherman DP. The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Mod Pathol 2010;23:874-80.

14. Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 2002;21:391-6.

15. Guglielmi S, Merz TM, Gugger M, Suter C, Nicod LP. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 2008;31:213-7.